AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34475328 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting the NLRP3 inflammasome and the IL-1 pathway as a new therapeutic approach.
Number of subjects: 0
Study 34475328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-modifying therapy combined with inflammatory modulation.
Number of subjects: 0
Study 32951729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of baru almond oil (BG)
Number of subjects: 29
Study 32951729 — intervention group
Group type: COMPARATOR
Intervention: 5 g of mineral oil (placebo, BP)
Number of subjects: 29
Study 35872749 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactiplantibacillus plantarum L-137 (HK L-137)
Number of subjects: 80
Study 35872749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32758033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation; cessation+exposure reduction
Number of subjects: 623
Study 32758033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation+exposure reduction
Number of subjects: 623
Study 32758033 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos
Number of subjects: 623
Study 32758033 — intervention group
Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 623
Study 35628138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in AGEs
Number of subjects: 70
Study 35628138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in AGEs
Number of subjects: 70
Study 34151710 — intervention group
Group type: EXPERIMENTAL
Intervention: DANBIO app
Number of subjects: 60
Study 34151710 — intervention group
Group type: COMPARATOR
Intervention: Touchscreen
Number of subjects: 60
Study 32630697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (specifics not provided)
Number of subjects: 0
Study 32630697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 33692620 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Number of subjects: 42
Study 34481965 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel; coverage rate of 93.51% (1990/2128)
Number of subjects: 2128
Study 34481965 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole; coverage rate of 95.25% (2027/2128)
Number of subjects: 2128
Study 34481965 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated children; 31.63% (31/98) reported being unaware of the campaign; 26.53% (26/98) were unable to reach distribution points.
Number of subjects: 2128
Study 34481965 — intervention group
Group type: EXPERIMENTAL
Intervention: Health workers' suggestions; increasing incentives for distribution.
Number of subjects: 2128
Study 32961806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 1: 120 kVp, 25 mAs
Number of subjects: 91
Study 32961806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 2: 100 kVp, 15 mAs
Number of subjects: 91
Study 32961806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 3: 120 kVp, 5 mAs
Number of subjects: 91
Study 32961806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 4: 100 kVp, 5 mAs
Number of subjects: 91
Study 32961806 — intervention group
Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 91
Study 32813283 — intervention group
Group type: COMPARATOR
Intervention: 10-day remdesivir regimen
Number of subjects: 0
Study 32813283 — intervention group
Group type: COMPARATOR
Intervention: 5-day remdesivir regimen
Number of subjects: 0
Study 34017122 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines stimulation
Number of subjects: 0
Study 34017122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitumor induction therapy
Number of subjects: 0
Study 32354072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon peptide (BMP) mcIRBP-19
Number of subjects: 142
Study 32354072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 35987467 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam plus metronidazole
Number of subjects: 0
Study 35987467 — intervention group
Group type: COMPARATOR
Intervention: meropenem plus placebo
Number of subjects: 0
Study 33763656 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus complete mesogastric excision (D2+CME)
Number of subjects: 34
Study 33763656 — intervention group
Group type: COMPARATOR
Intervention: Conventional D2 radical surgery
Number of subjects: 34
Study 34599455 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiSense lead with optimized settings
Number of subjects: 110
Study 34599455 — intervention group
Group type: COMPARATOR
Intervention: Tendril lead
Number of subjects: 110
Study 35978334 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components (motivational counseling, nicotine replacement patches/lozenges, message framing)
Number of subjects: 1152
Study 35978334 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components
Number of subjects: 1152
Study 35978334 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation processes (reach, fidelity, acceptability, appropriateness, sustainability, and cost)
Number of subjects: 1152
Study 34023028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intradialytic cycling program
Number of subjects: 0
Study 34023028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34906386 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting (AFG) protocol with a single injection of autologous fat grafting and dressed with nano fat (Group A)
Number of subjects: 100
Study 34906386 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of serial dressings with 1% silver sulphadiazine or other topical agents (Group B)
Number of subjects: 100
Study 33829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary fiber intake in participants with the highest tertile of SCFA PGS
Number of subjects: 424
Study 33829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of SCFA PGS
Number of subjects: 424
Study 33829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of SCFA PGS
Number of subjects: 424
Study 35466952 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin for neuroprotection in PD (part of the PD STAT trial)
Number of subjects: 235
Study 35466952 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative insights from care partners
Number of subjects: 235
Study 35466952 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative insights from research staff
Number of subjects: 235
Study 33882225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (5×10^10 viral particles)
Number of subjects: 39321
Study 33882225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39321
Study 32538219 — intervention group
Group type: COMPARATOR
Intervention: Microneedling (MN) only
Number of subjects: 40
Study 32538219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined microneedling-platelet-rich plasma (MN-PRP)
Number of subjects: 40
Study 33217833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided deep serratus anterior plane block (Group D)
Number of subjects: 50
Study 33217833 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided superficial serratus anterior plane block (Group S)
Number of subjects: 50
Study 34529000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel plus investigational agents (graduated treatments)
Number of subjects: 938
Study 34529000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel plus investigational agents (non-graduated treatments)
Number of subjects: 938
Study 34529000 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant paclitaxel plus chemotherapy alone (control)
Number of subjects: 938
Study 32954969 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA)
Number of subjects: 6
Study 32954969 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 6
Study 34251303 — intervention group
Group type: EXPERIMENTAL
Intervention: LBAL (adalimumab biosimilar candidate)
Number of subjects: 383
Study 34251303 — intervention group
Group type: COMPARATOR
Intervention: adalimumab reference product (ADL)
Number of subjects: 383
Study 34251303 — intervention group
Group type: EXPERIMENTAL
Intervention: LBAL (after 24 weeks)
Number of subjects: 383
Study 34251303 — intervention group
Group type: COMPARATOR
Intervention: ADL (after 24 weeks)
Number of subjects: 383
Study 34251303 — intervention group
Group type: EXPERIMENTAL
Intervention: LBAL and ADL
Number of subjects: 383
Study 33115851 — intervention group
Group type: COMPARATOR
Intervention: Weekend admissions
Number of subjects: 4000
Study 34870602 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and self-regulation arm (8 modules, 17 sessions)
Number of subjects: 0
Study 34870602 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation arm (7 modules, 17 sessions)
Number of subjects: 0
Study 34870602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm (full toolkit, 15 modules, 34 sessions)
Number of subjects: 0
Study 34870602 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study 34123529 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band training
Number of subjects: 20
Study 34123529 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 20
Study 34123529 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 34123529 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 20
Study 33081596 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutritional intervention
Number of subjects: 36
Study 33081596 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face intervention
Number of subjects: 36
Study 36018367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement plug (Group II)
Number of subjects: 114
Study 36018367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone plug (Group I)
Number of subjects: 114
Study 36018367 — intervention group
Group type: COMPARATOR
Intervention: Empty canal (Group III)
Number of subjects: 114
Study 36018367 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 114
Study 36348045 — intervention group
Group type: EXPERIMENTAL
Intervention: LE massage 3 times a week for 4 weeks
Number of subjects: 71
Study 36348045 — intervention group
Group type: EXPERIMENTAL
Intervention: LE massage 2 times a week for 6 weeks
Number of subjects: 71
Study 36348045 — intervention group
Group type: COMPARATOR
Intervention: Head/neck/shoulder massage (control) 3 times a week for 4 weeks
Number of subjects: 71
Study 36348045 — intervention group
Group type: COMPARATOR
Intervention: Head/neck/shoulder massage (control) 2 times a week for 6 weeks
Number of subjects: 71
Study 35717610 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based home workout program for shift-work nurses for 18 weeks, including text-message counseling for the first 12 weeks and environmental improvement for the remaining weeks.
Number of subjects: 54
Study 35717610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-Tex suture (2-0 Gore-Tex; W. L. Gore & Associates, Inc.)
Number of subjects: 200
Study 33515745 — intervention group
Group type: COMPARATOR
Intervention: Polydioxanone suture (2-0 polydioxanone suture)
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sexual function at 1 year
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dyspareunia rates
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of women sexually active at 1 year
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal status of women sexually active at 1 year
Number of subjects: 200
Study 33515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy status of women sexually active at 1 year
Number of subjects: 200
Study 32759543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA)
Number of subjects: 42
Study 32759543 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with 2.5 mg/day rosuvastatin
Number of subjects: 42
Study 33583759 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue/platelet-poor plasma
Number of subjects: 72
Study 33583759 — intervention group
Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 72
Study 32812652 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB + PCEA (5 ml bolus every hour, 5 ml PCEA bolus lockout 20 minutes)
Number of subjects: 150
Study 32812652 — intervention group
Group type: COMPARATOR
Intervention: CEI + PCEA (5 ml/h, 5 ml PCEA bolus, lockout 20 minutes)
Number of subjects: 150
Study 32812652 — intervention group
Group type: COMPARATOR
Intervention: CEI + PCEA
Number of subjects: 150
Study 32812652 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB + PCEA
Number of subjects: 150
Study 36197197 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive somatosensory stimulation along with UE motor program (Gr2)
Number of subjects: 37
Study 36197197 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation along with UE motor program (Gr1)
Number of subjects: 37
Study 36197197 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Gr1 and Gr2
Number of subjects: 37
Study 33772508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) therapy
Number of subjects: 227
Study 33772508 — intervention group
Group type: COMPARATOR
Intervention: Control (adjustment of antiepileptic drugs)
Number of subjects: 227
Study 32791671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy
Number of subjects: 40
Study 32791671 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study 35472141 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative denosumab, curettage and adjuvant local therapy (Arm B)
Number of subjects: 18
Study 35472141 — intervention group
Group type: COMPARATOR
Intervention: Curettage and adjuvant local therapy (Arm A)
Number of subjects: 18
Study 34721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Huayu‐Qiangshen‐Tongbi formula (HQT) plus methotrexate (MTX)
Number of subjects: 22
Study 34721377 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide (LEF) plus methotrexate (MTX)
Number of subjects: 22
Study 33090945 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade IV posteroanterior central and unilateral Maitland mobilization
Number of subjects: 60
Study 33090945 — intervention group
Group type: COMPARATOR
Intervention: Grade I mobilization (Placebo)
Number of subjects: 60
Study 32155315 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (25 mg)
Number of subjects: 0
Study 32155315 — intervention group
Group type: COMPARATOR
Intervention: Tetrabenazine (25 mg)
Number of subjects: 0
Study 34427633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg every 4 weeks
Number of subjects: 268
Study 32240350 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% low-dose images
Number of subjects: 298
Study 32240350 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose images
Number of subjects: 298
Study 32240350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose images
Number of subjects: 298
Study 35483753 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 3693
Study 32980791 — intervention group
Group type: COMPARATOR
Intervention: 2D-SWE in normal pregnancies
Number of subjects: 259
Study 32980791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-SWE in A1GDM pregnancies
Number of subjects: 259
Study 32980791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-SWE in A2GDM pregnancies
Number of subjects: 259
Study 35491524 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg with exenatide-matched placebo
Number of subjects: 0
Study 35491524 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice-daily 10 μg with dapagliflozin-matched placebo
Number of subjects: 0
Study 35491524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus exenatide
Number of subjects: 0
Study 35491524 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 0
Study 35293879 — intervention group
Group type: EXPERIMENTAL
Intervention: Double tear reservoir lens with 5.0-mm back optic zone diameter
Number of subjects: 65
Study 35293879 — intervention group
Group type: COMPARATOR
Intervention: Euclid with 6.2-mm back optic zone diameter (aged <14 years)
Number of subjects: 65
Study 35293879 — intervention group
Group type: COMPARATOR
Intervention: Euclid with 6.2-mm back optic zone diameter (aged ≥14 years)
Number of subjects: 65
Study 35293879 — intervention group
Group type: COMPARATOR
Intervention: Double tear reservoir lens with 6.0-mm back optic zone diameter
Number of subjects: 65
Study 32439135 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC) for six sessions, once a week for two hours (n = 40)
Number of subjects: 80
Study 32439135 — intervention group
Group type: COMPARATOR
Intervention: Antenatal Usual Care (AUC) (n = 40)
Number of subjects: 80
Study 32439135 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC)
Number of subjects: 80
Study 32439135 — intervention group
Group type: COMPARATOR
Intervention: Antenatal Usual Care (AUC)
Number of subjects: 80
Study 32439135 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC) and Antenatal Usual Care (AUC)
Number of subjects: 80
Study 35689462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 117
Study 35689462 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 117
Study 33055581 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving protein goals within 4 days
Number of subjects: 274
Study 33055581 — intervention group
Group type: EXPERIMENTAL
Intervention: Failing to achieve protein goals
Number of subjects: 274
Study 32046931 — intervention group
Group type: EXPERIMENTAL
Intervention: MET‐LIRA (MET-2000 mg, LIRA 1.8 mg SC QD)
Number of subjects: 153
Study 32046931 — intervention group
Group type: COMPARATOR
Intervention: MET‐P (MET-2000 mg, Placebo QD)
Number of subjects: 153
Study 35301896 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block group (ESP block before anesthesia)
Number of subjects: 0
Study 35301896 — intervention group
Group type: COMPARATOR
Intervention: non-ESP group (no intervention)
Number of subjects: 0
Study 33011539 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 343
Study 35405248 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (METF) for 2 weeks
Number of subjects: 16
Study 35405248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON) for 2 weeks
Number of subjects: 16
Study 34050768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (POS) prophylaxis for 7 days
Number of subjects: 88
Study 34050768 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care only (SOC)
Number of subjects: 88
Study 32444129 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity parameters (BMI, WHR, VFA)
Number of subjects: 344
Study 32444129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat tissue parameters (BFM, FFM, VFA, TSFA, PBF)
Number of subjects: 344
Study 32444129 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness parameters (baPWV left, baPWV right, cfPWV)
Number of subjects: 344
Study 36330556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent graft (SG) and paclitaxel-coated balloon (PCB)
Number of subjects: 80
Study 36330556 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB) alone
Number of subjects: 80
Study 33085036 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-processing technique for assessing damage
Number of subjects: 50
Study 33085036 — intervention group
Group type: COMPARATOR
Intervention: Expert observations
Number of subjects: 50
Study 36126857 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program (QIP) implemented in 2016
Number of subjects: 1716
Study 36126857 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program (QIP)
Number of subjects: 1716
Study 36126857 — intervention group
Group type: COMPARATOR
Intervention: Non-QIP (before QIP implementation)
Number of subjects: 1716
Study 34167827 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg CTC (equivalent to 112-mg celecoxib and 88-mg tramadol)
Number of subjects: 36
Study 34167827 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg tramadol
Number of subjects: 36
Study 34167827 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg celecoxib
Number of subjects: 36
Study 34167827 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg celecoxib plus 100-mg tramadol
Number of subjects: 36
Study 34167827 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 32220636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnosis using MALDI-TOF MS
Number of subjects: 8628
Study 36369081 — intervention group
Group type: EXPERIMENTAL
Intervention: Body wash with white Marshmallow extract
Number of subjects: 92
Study 36369081 — intervention group
Group type: COMPARATOR
Intervention: Control group with lukewarm water
Number of subjects: 92
Study 32744106 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1-based therapy
Number of subjects: 8711
Study 32783547 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX, hydroxychloroquine plus vitamin D supplementation for 3 months
Number of subjects: 40
Study 32783547 — intervention group
Group type: COMPARATOR
Intervention: MTX plus hydroxychloroquine
Number of subjects: 40
Study 32783547 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 40